Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
China Pharmacy ; (12): 86-90, 2023.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-953724

RESUMO

OBJECTIVE To establish evaluation criteria for rational drug use of atosiban in clinic, and to provide reference for rational drug use of atosiban in clinic. METHODS Based on the drug instructions of atosiban acetate injection and related guidelines, the experts of the Evaluation Group of Rational Drug Use formulated the evaluation criteria of rational drug use, including 5 primary indexes and 8 secondary indexes. The weight coefficients of secondary indexes were calculated by analytic hierarchy process (AHP), and the use of atosiban acetate injection in 190 pregnant women from the Third Affiliated Hospital of Guangzhou Medical University (referred to as “our hospital”) was evaluated retrospectively by technique for order preference by similarity to an ideal solution (TOPSIS). The evaluation results were divided into three levels including reasonable, basic reasonable and unreasonable application based on the relative approach degree. RESULTS Among 190 pregnant women, 49 (25.8%) were treated with atosiban reasonably, 39 (20.5%) were treated with atosiban basic reasonably, and 102 (53.7%) were treated with atosiban unreasonably. The evaluation results obtained by AHP-TOPSIS method were consistent with the actual situation in clinic. The main problems of the unreasonably use were super indications, unreasonable usage and dosage, over the course of treatment and the lack of proper economic consideration. CONCLUSIONS The rationality evaluation criteria of atosiban’s clinical application are established by AHP-TOPSIS method; the evaluation results obtained by this method are quantifiable, scientific and reliable. The unreasonable use of atosiban is common in our hospital, and the management should be strengthened in clinical application.

2.
China Pharmacy ; (12): 264-268, 2019.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-816734

RESUMO

OBJECTIVE: To provide reference for rational use of estradiol (E2) preparation in clinic. METHODS: The medical records of outpatients receiving assisted reproductive technology (ART) and E2 preparation [Estradiol valerate tablets (EV), Complex packing estradiol tablets/estradiol and dydrogesterone tablets (EP), Estradiol gel (EG)] were collected from the reproductive medicine center of a hospital during Jan. 2016-Mar. 2017. Taking drug instruction as standard, the rationality of medical records was evaluated from aspects of indication, route of administration, contraindication, usage and dosage, treatment course, etc. At the same time, these patients were followed up by telephone or outpatient service, and their pregnancy outcomes and ADR were summarized. RESULTS: A total of 12 646 prescriptions were collected, and 7 222, 3 912, 181 and 1 331 prescriptions used EV, EP, EG and EV+EP, respectively. The types of off-label use included over-indication, over-route and over-contraindication, and the rates of off-label use rates were 100%, 11.73% and 43.60%, respectively. A total of 5 868 ART patients were involved; 439 patients received fresh embryo transplantation, and 5 429 patients received frozen-thawed embryo transplantation, involving 720 and 11 926 prescriptions, respectively. The rates of off-label use of above E2 preparations were 100% (except for fresh embryo transplantation patients using EG). As of Feb. 2018, the infant-holding rates of ART patients using EV, EP, EG and EV+EP were 85.29%, 85.37%, 86.36% and 85.45%, respectively. No relevant ADR and neonatal birth defect was found. CONCLUSIONS: The phenomenon of off-label use of E2 preparations is widespread in the reproductive medicine center of the hospital. Although there is no indication of related safety risks, evidence-based evaluation should be carried out by enlarging the sample size in clinical practice, and careful use.

3.
Chongqing Medicine ; (36): 1211-1213, 2014.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-448195

RESUMO

Objective To investigate the protective effect of cryptotanshinone (CTS) and donepezil(DON) on amyloid-βprotein (Aβ)-induced apoptosis in SH-SY5Y cells .Methods SH-SY5Y cells were cultured in vitro for establishing the Alzheimer disease (AD) model .The cell viability was detected by the MTT assay .The apoptosis rate was measured by Hoechst 33342 and the expres-sion of Bcl-2 and Bax was detected by Western blot .Results CTS ,DON and their combination could obviously alleviate Aβ-caused injury of SH-SY5Y cells ,increase the cell survival rate ,remarkably up-regulate the expression of Bcl-2 protein ,decrease the expres-sion of Bax protein and inhibit the apoptosis .The effect of the CTS and DON combination for inhibiting apoptosis was significantly stronger than that of the single use of CTS and DON ,the difference had statistical significance(P<0 .05) .Conclusion The combi-nation of CTS and DON has the synergistic protective effect on Aβ-caused injury in SH-SY5Y cells ,its mechanisms may be related with the cooperation regulation of the expression of apoptosis related gene Bcl-2 protein family .

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...